494224-20-3

Upstream product

• 256382-39-5 {2-[(3-methoxymethyl-phenyl)methyl]-2-oxo-ethyl}phosphonic acid dimethyl ester 
• 346672-53-5 ethyl (R)-7-(2-formyl-5-oxopyrrolidin-1-yl)heptanoate 
• 346672-96-6 ethyl 7-[(2R)-2-(tert-butyldimethylsilyloxy)methyl-5-oxo-1-pyrrolidinyl]heptanoate 
• 346672-97-7 ethyl 7-[(2R)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]heptanoate 
• 128899-30-9 (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 
• 29823-18-5 ethyl 7-bromoheptanoate 

Downstream Products

• 494221-64-6 7-((2R)-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxopyrrolidin-1-yl)heptanoic acid 
• 494221-63-5 ethyl 7-[(2R)-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]heptanoate 

Relevant academic research and scientific papers

Discovery of an 8-aza-5-thiaProstaglandin E1 analog as a highly selective EP4 receptor agonist

For the purpose of discovering an orally available EP4 subtype-selective agonist, a series of 8-aza prostaglandin E1 (PGE1) analogs were synthesized and evaluated for their affinity for PGE2 receptor subtypes. Additionally

REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT

A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor

Analogues of PGE2 wherein the hydroxycyclopentanone ring has been replaced by a lactam have been prepared and evaluated as ligands for the EP4 receptor. An optimized compound (19a) shows high potency and agonist efficacy at the EPsu